Key Drivers
- Strong Cash Flow
- Elevated Leverage
- Dividend Pressure
AIAI Summary
GSK is a cash-generative but execution-dependent capital-redeployment story: its valuation discount offers upside only if Specialty Medicines, long-acting HIV and oncology launches replace the 2028–30 dolutegravir cliff without further acquisition impairments or balance-sheet strain.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Elevated Leverage
- •Dividend Pressure
GSK combines strong profitability and cash generation with elevated leverage, weak liquidity, and near-term dividend coverage risk despite a moderate valuation.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Support defended
- •Resistance active
GSK remains mildly bearish over the last month, with support at $48.10 and a bullish trigger above $51.10 toward $52.10–$52.40.
Rebound from $48.12 to $51.06 before retreating
Sentiment & News
Key News Insights:
- •Cost Savings
- •Oncology Expansion
- •Patent Risk
GSK is funding oncology and specialty-medicine pipeline growth through £1.9bn savings, but HIV patent-cliff risks and cautious sentiment temper the outlook.
Pipeline investment supports long-term growth, but near-term valuation may remain constrained by patent-cliff uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings